

THE FUNGITELL® ASSAY REFERENCE LIST

Selected references for clinical, pre-clinical and basic research involving diagnostic (1→3)-β-D-glucanemia

Categories:

A. Fungitell® Diagnostic Performance

B. (1→3)-β-D-Glucan Kinetics

C. (1→3)-β-D-Glucan & Galactomannan: Relative Diagnostic Performance

D. (1→3)-β-D-Glucan Meta-Analyses

E. (1→3)-β-D-Glucan Reagent-Related

F. Clinical Guideline-Related

G. Clinical Mycology Reviews

H. Miscellaneous

A. Fungitell® Diagnostic Performance

- Rouzé, A., Loidant, S., Poissy, J., Dervaux, B., Sendid, B., Cornu, M., and Nseir, S.; S-TAFE study group. (2017). Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial. *Intensive Care Med.* 2017 Sep 22. doi: 10.1007/s00134-017-4932-8.
- Giacobbe, D.R., Mikulska, M., Tumbarello, M., Furfaro, E., Spadaro, M., Losito, A.R., Mesini, A., De Pascale, G., Marchese, A., Bruzzone, M., Pelosi, P., Mussap, M., Molin, A., Antonelli, M., Posteraro, B., Sanguinetti, M., Viscoli, C., and Del Bono, V.; ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). (2017). Combined use of serum (1→3)-β-D-glucan and procalcitonin for the early differential diagnosis between candidaemia and bacteraemia in intensive care units. *Crit. Care.* 21:176.
- Pang, Y.K., Ip, M., You, J.H., (2017). Potential clinical and economic outcomes of active beta-D-glucan surveillance with preemptive therapy for invasive candidiasis at intensive care units: a decision model analysis. *Eur. J. Clin. Microbiol. Infect. Dis.* 36:187-194.
- Rautemaa, V., Green, H.D., Jones, A.M., and Rautemaa-Richardson, R. (2017). High level of β-(1,3)-D-glucan antigenaemia in cystic fibrosis in the absence of invasive fungal disease. *Diagn Microbiol Infect Dis.* 88:316-321.
- Nucci, M., Nouér, S.A., Esteves, P., Guimarães, T., Breda, G., de Miranda, B.G., Queiroz-Telles, F., and Colombo, A.L. (2016) Discontinuation of empirical antifungal therapy in ICU patients using 1,3-β-D-glucan. *J Antimicrob Chemother.* 71:2628-33.
- Posteraro, B., Tumbarello, M., De Pascale, G., Liberto, E., Vallecoccia, M.S., De Carolis, E., Di Gravio, V., Trecarichi, E.M., Sanguinetti, M., and Antonelli, M. (2016). (1→3)-β-D-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study. *J Antimicrob Chemother.* 71:2262-9.
- Prattes, J., Raggam, R.B., Vanstraelen, K., Rabensteiner, J., Hoegenauer, C., Krause, R., Prüller, F., Wölfler, A., Spriet, I., and Hoenigl, M. (2016). Chemotherapy-Induced Intestinal Mucosal Barrier Damage: a Cause of Falsely Elevated Serum (1→3)-β-D-Glucan Levels? *J. Clin. Microbiol.* 54:798-801.
- Ceesay, M.M., Desai, S.R., Berry, L., Cleverley, J., Kibbler, C.C., Pomplun, S., Nicholson, A.G., Douiri, A., Wade, J., Smith, M., Mufti, G.J., and Pagliuca, A., (2015). A comprehensive diagnostic approach using galactomannan, targeted β-D-glucan, baseline computerized tomography and biopsy yields a significant burden of invasive fungal disease in at risk haematology patients. *Br J Haematol.* 168:219-29.
- Raggam, R.B., Fischbach, LM., Prattes, J., Duettmann, W., Eigl, S., Reischies, F., Wölfler, A., Rabensteiner, J., Pruellner, F., Krause, R., and Hoenigl, M. (2015). Detection of (1→3)-β-D-glucan in same-day urine and serum samples obtained from patients with haematological malignancies. *Mycoses.* 58:394-8.
- Hammarström, H., Kondori, N., Friman, V., and Wennerås, C. (2015). How to interpret serum levels of beta-glucan for the diagnosis of invasive fungal infections in adult high-risk hematology patients: optimal cut-off levels and confounding factors. *Eur J. Clin. Microbiol Infect Dis.* 34:917-25.
- Ostrosky-Zeichner, L., et al., (2014) MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by pre-emptive therapy for invasive candidiasis in high risk adults in the critical care setting. *Clin. Infect. Dis.* 58:1219-26.
- Esteves, F., et al., (2014). (1→3)-β-D-glucan in association with lactate dehydrogenase as biomarkers of *Pneumocystis pneumonia* (PCP) in HIV-infected patients. *Eur. J. Clin. Microbiol. Infect. Dis.* 33:1173–1180.
- Prattes, J., Hoenigl, M., Rabensteiner, J., Raggam, R.B., Pruellner, F., Zollner-Schwetz, I., Valentin, T., Hoenigl, K., Fruhwald, S., and Krause, R. (2014). Serum (1→3)-β-D-glucan for antifungal treatment stratification at the intensive care unit and the influence of surgery. *Mycoses.* 57:679-86.
- Fernandez-Silva, F., et al., (2014). Experimental murine acromionosis: an emerging opportunistic human infection. *Med. Mycol.* 52: 29-35.
- Chen, M., et al., (2013). Pulmonary fungus ball caused by *Penicillium capsulatum* in a patient with type 2 diabetes: A case report. *BMC Infectious Diseases* 13:496-500.
- Edathodu, J., et al., (2013) Invasive fungal infection due to *Triadelpia pulvinata* in a patient with acute myeloid leukemia. *J. Clin. Microbiol.* 51:3426–9.
- Goudjil, S., et al., (2013). (1→3)-β-D-glucan levels in candidiasis infections in the critically ill neonate. *J. Maternal-Fetal & Neonatal Med.* 26:44-8.
- Racil, Z., Kocmanova, I., Toskova, M., Winterova, J., Lengerova, M., Timilsina, S., Mayer, J., (2013). Reactivity of the (1→3)-β-D-glucan assay during bacteraemia: limited evidence from a prospective study. *Mycoses.* 56:101-4.
- Damiani, C., et al., (2013). Combined Quantification of Pulmonary *Pneumocystis jirovecii* DNA and Serum (1→3)-β-D-Glucan for Differential Diagnosis of *Pneumocystis* Pneumonia and *Pneumocystis* Colonization. *J. Clin. Micro.* 51: 3380-3388.
- De Pascale, G., Posteraro, B., Cutuli, S.L., Caricato, A., Lepore, D., Tumbarello, M., Pennisi, M.A., Sanguinetti, M., and Antonelli, M. (2013). Why should we monitor (1→3)-β-D-glucan levels during invasive candidiasis? Just ask your ophthalmologist! *J. Clin. Microbiol.* 51:1645-6.
- Held, J., et al., (2013). Comparison of (1→3)-β-D-glucan, mannan/anti-mannan antibodies, and Cand-Tec *Candida* antigen as serum biomarkers for Candidemia. *J. Clin. Micro.* 51:1158-1164.
- Tissot, F., et al., (2013). Beta-Glucan antigenemia anticipates diagnosis of blood culture-negative intra-abdominal candidiasis. *Am. J. Resp. Crit. Care Med.* 188:1100-9.
- Metan, G., Koç, A.N., Kaynar, L.G., Atalay, A., Oztürk, A., Eser, B., Cetin, M., (2013). What is the role of the (1→3)-β-D-glucan assay in the screening of patients undergoing autologous haematopoietic stem-cell transplantation? *Mycoses.* 56:34-8.
- Lobo, M.L., Esteves, F., de Sousa, B., Cardoso, F., Cushion, M.T., Antunes, F., Matos, O., (2013). Therapeutic potential of caspofungin combined with trimethoprim sulfamethoxazole for *Pneumocystis pneumonia*: a pilot study in mice. *PLoS One.*8(8):e70619. doi: 10.1371/journal.pone.0070619.
- Hoarau, G., et al., (2013). Detection of (1→3)-β-D-glucans in situ in a *Candida albicans* brain granuloma. *J. Infect.* 67: 622-4.
- Wood, B.R., et al., (2013). Test performance of blood beta-glucan for *Pneumocystis jirovecii* pneumonia in patients with AIDS and respiratory symptoms. *AIDS* 27: 967-972.



THE FUNGITELL® ASSAY REFERENCE LIST

Selected references for clinical, pre-clinical and basic research involving diagnostic (1→3)-β-D-glucanemia

27. Lengerova, M., Kocmanova, I., Racil, Z., Hrnčirova, K., Pospisilova, S., Mayer, J., Najvar, L.K., Wiederhold, N.P., Kirkpatrick, W.R., Patterson, T.F., (2012). Detection and measurement of fungal burden in a guinea pig model of invasive pulmonary aspergillosis by novel quantitative nested real-time PCR compared with galactomannan and (1→3)-β-D-glucan detection. *J. Clin. Microbiol.* 50:602-8.
28. Duffner, U., Abdel-Mageed, A., Dahl, K., Fogg, G. and Hester, J. (2012). Serum (1→3)-β-D-glucan levels (Fungitell® assay) is not useful as a screening test for recipients of an allogeneic HSCT while on immunoglobulin replacement. *Bone Marrow Transpl.* 47: 151–152.
29. Metan, G., Koç, A.N., Atalay, A., Kaynar, L.G., Ozturk, A., Alp, E., Eser B., (2012). What should be the optimal cut-off of serum (1→3)-β-D-glucan for the detection of invasive pulmonary aspergillosis in patients with haematological malignancies? *Scand. J. Infect. Dis.* 44:330-6.
30. Metan, G., Koç, A.N., Agkus, C., Kaynar, L.G., Alp, E., Eser, B., (2012). Can bacteraemia lead to false positive results in (1→3)-β-D-glucan test? Analysis of 83 bacteraemia episodes in high-risk patients for invasive fungal infections. *Rev. Iberoam Micol.* 29:169-71.
31. Ginocchio, F., et al., (2012). Case report of the reliability of (1→3)-β-D-glucan monitoring during the treatment of peritoneal candidiasis in a child receiving continuous peritoneal dialysis. *Clin. Vacc. Immunol.* 19: 626-7.
32. Hanson, K.E. et al., (2012). β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: A randomized pilot study. *PLoS One* 7: e42282.
33. Sax, P.E., Komarow, L., Finkelman, M., Grant, P.M., Andersen, J., Scully, E., Powderly, W.G. and Zolopa, A.R., for the AIDS Clinical Trials Group Study A5164 Team., (2011). Blood (1→3)-β-D-Glucan as a diagnostic test for HIV-related *Pneumocystis jirovecii* pneumonia. *Clin. Inf. Dis.* 53:197-202.
34. Held, J., Koch, M., Reischl, U., Danner, T., Serr, A., (2011). Serum (1→3)-β-D-Glucan measurement as early indicator for *Pneumocystis jirovecii* pneumonia and evaluation of its prognostic value. *Clin. Microbiol. Infect.* 17: 595-602
35. Sanada, Y., et al., (2012). The efficacy of measurement of serum beta-D-glucan in patients with biliary atresia. *Pediatric. Surg. Int'l.* 28: 993-996.
36. Bellanger, A.P., Grenouillet, F., Henon, T., Skana, F., Legrand, F., Deconinck, E., Millon, L., (2011). Retrospective assessment of β-D-(1,3)-glucan for presumptive diagnosis of fungal infections. *APMIS.* 119:280-6.
37. Yoshida, K., et al., (2011). Clinical viability of Fungitell®, a new (1→3)-β-D-glucan measurement kit, for diagnosis of invasive fungal infection, and comparison with other kits available in Japan. *J. Infect. Chemother.* 17: 473-477.
38. Chowdhary, A., Randhawa, H.S., Singh, V., Khan, Z.U., Ahmad, S., Kathuria, S., Roy, P., Khanna, G., Chandra, J., (2011). *Bipolaris hawaiiensis* as etiologic agent of allergic bronchopulmonary mycosis: first case in a paediatric patient. *Med. Mycol.* 49:760-5. C101.
39. De Vlieger, G., Lagrou, K., Maertens, J., Verbeke, E., Meersseman, W., Van Wijngaerden, E., (2011). Beta-D-glucan detection as a diagnostic test for invasive aspergillosis in immunocompromised critically ill patients with symptoms of respiratory infection: an autopsy-based study. *J. Clin. Microbiol.* 49:3783-7.
40. Del Bono, V., Delfino, E., Furfaro, E., Mikulska, M., Nicco, E., Bruzzi, P., Mularoni, A., Bassetti, M., Viscoli, C., (2011). Clinical Performance of the (1→3)-β-D-Glucan Assay in Early Diagnosis of Nosocomial *Candida* Bloodstream Infections. (2011). *Clin. Vaccine Immunol.* 18:2113-7.
41. Metan, G., Agkus, C., Koç, A.N., Elmali, F., Finkelman, M.A., (2011). Does ampicillin-sulbactam cause false positivity of (1→3)-β-D-glucan assay? A prospective evaluation of 15 patients without invasive fungal infections *Mycoses.* 55: 366-71.
42. Montagna, M.T., Coretti, C., Lovero, G., De Giglio, O., Montagna, O., Laforgia, N., Santoro, N., Caggiano, G., (2011). Diagnostic Performance of (1→3)-β-D-Glucan in Neonatal and Pediatric Patients with Candidemia. *Int. J. Mol. Sci.* 12:5871-7.
43. Eggimann, P., Marchetti, O., (2011). Is (1→3)-β-D-glucan the missing link from bedside assessment to pre-emptive therapy of invasive candidiasis? *Crit. Care.* 15:1017.
44. Gonzales, B.E., Faverio, L.A., Marty, F.M., MacArthur, C. and Churchill, R.B., (2011). Elevated serum beta-D-glucan levels in immunocompromised children with clinical suspicion for *Pneumocystis jirovecii* pneumonia. *Clin. Vacc. Immunol.* 18: 1202–1203.
45. Posteraro, B., De Pascale, G., Tumbarello, M., Torelli, R., Pennisi, M.A., Bello, G., Maviglia, R., Fadda, G., Sanguinetti, M., Antonelli, M., (2011). Early diagnosis of Candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-D-glucan assay, *Candida* score, and colonization index. *Crit. Care.* 22;15:R249
46. Heyland, D., Jiang, X., Day, A.G. and Laverdiere, M., (2011). Serum β-D-glucan of critically ill patients with suspected ventilator-associated pneumonia: Preliminary observations. *J. Crit. Care.* 5: 536.e1-536.e9.
47. Mackay, C.A., Ballot, D.E., Perovic, O., (2011). Serum (1→3)-β-D-Glucan assay in the diagnosis of invasive fungal disease in neonates. *Pediatr Rep.* 16;3:e14.
48. Mohr, J.F., Sims, C., Paetznick, V., Rodriguez, J., Finkelman, M.A., Rex, J.H., and Ostrosky-Zeichner, L., (2011). A prospective survey of (1→3)-β-D-glucan and its relationship to Invasive candidiasis in the surgical ICU setting. *J. Clin. Microbiol.* 49: 58-61.
49. Mokaddas, E., Khan, Z.U., Ahmad, S., Nampoory, M.R., Burhamah, M., (2011). Value of (1→3)-β-D-glucan, *Candida* mannan and *Candida* DNA detection in the diagnosis of candidaemia. *Clin. Microbiol. Infect.* 17:1549-53.
50. Metan, G., Agkus C., Buldu, H., Koç, A.N., (2010). The interaction between piperacillin/tazobactam and assays for *Aspergillus* galactomannan and (1→3)-β-D-glucan in patients without risk factors for invasive fungal infections *Infection.* 38:217-21.
51. Mularoni, A., Furfaro, E., Faraci, M., Franceschi, A., Mezzano, P., Bandettini, R., Viscoli, C., and Castagnola, E., (2010). High Levels of beta-D-glucan in immunocompromised children with proven invasive fungal disease. *Clin. Vaccine Immunol.* 17:882-3.
52. Alexander, B.D., Smith, P.B., Davis, R.D., Perfect, J.R., Reller, L.B., (2010). The (1→3)-β-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. *J. Clin. Microbiol.* 48: 4083-8.
53. Del Palacio, A., Llenas-García, J., Soledad Cuétara, M., Pulido, F., Rubio, R., Pontón, J., Del Palacio-Pérez-Medel, A., (2010). Serum (1→3)-β-D-Glucan as a noninvasive adjunct marker for the diagnosis and follow-up of *Pneumocystis jirovecii* pneumonia in patients with HIV infection. *Clin. Infect. Dis.* 50:451-2.
54. Racil, Z., Kocmanova, I., Lengerova, M., Weinbergerova, B., Buresova, L., Toskova, M., Winterova, J., Timilsina, S., Rodriguez, I., Mayer, J., (2010). Difficulties in using (1→3)-β-D-glucan as the screening test for the early diagnosis of invasive fungal diseases in patients with hematological malignancies - high frequency of false positive results and their analysis. *J. Med. Microbiol.* 59:1016-22.
55. Desmet, S., Van Wijngaerden, E., Maertens, J., Verhaegen, J., Verbeke, E., De Munter, P., Meersseman, W., Van Meensel, B., Van Eldere, J., Lagrou, K., (2009). Serum (1→3)-β-D-glucan as a tool for diagnosis of *Pneumocystis jirovecii* pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. *J. Clin. Microbiol.* 47:3871-4.



Reference List Publish Date:
September 2017

Corporate Headquarters
Associates of Cape Cod, Inc.
124 Bernard E. Saint Jean Drive
East Falmouth, MA 02536 USA
Tel: (508) 540-3444
www.acciusa.com

United Kingdom
Associates of Cape Cod Int'l., Inc.
Deacon Park, Moorgate Road
Knowsley, Liverpool L33 7RX
United Kingdom
Tel: (44) 151-547-7444
www.acciuk.co.uk

Europe
Associates of Cape Cod Europe, Inc.
Opelstrasse 14
D-64546 Mörfelden-Walldorf
Germany
Tel: (49) 61 05-96 10 0
www.acciusa.de

Page 2
PR#17-043

THE FUNGITELL® ASSAY REFERENCE LIST

Selected references for clinical, pre-clinical and basic research involving diagnostic (1→3)-β-D-glucanemia

56. Koo, S., Bryar, J.M., Page, J.H., Baden, L.R., and Marty, F.M., (2009). Diagnostic performance of the (1→3)-β-D-glucan assay for invasive fungal disease. *Clin. Infect. Dis.* 49:1650-9.
57. Ostrosky-Zeichner, L., Paetznick, V.L., Rodriguez, J., Chen, E. and Sheehan, D.J., (2009). Activity of anidulafungin in a murine model of *Candida krusei* infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1→3)-β-D-glucan levels. *Antimicrob. Agents Chemother.* 53: 1639-1641.
58. Ráčil, Z., Kocmanová, I., Weinbergerová, B., Winterová, J., Lengerová, M., Hrnčířová, K., Mayer, J., (2009). Detection of (1→3)-β-D-glucan for diagnosis of invasive fungal infections in hemato-oncological patients: usefulness for screening of invasive mycosis and for confirmation of galactomannan positive results]. *Klin. Mikrobiol. Infekc. Lek.* 15:48-57.
59. Cuetara, M.S., Alhambra, A., Moragues, M.D., Gonzalez-Elorza, E., Ponton, J., and Del Palacio, A. (2009). Detection of (1→3)-β-D-glucan as an adjunct to diagnosis in a mixed population with uncommon proven fungal diseases or unusual clinical presentation. *Clin. Vacc. Immunol.* 16: 423-426.
60. Del Bono, V., Mularoni, A., Furfaro, E., Delfino, E., Rosasco, L., Miletich, F., and Viscoli, C., (2009). clinical evaluation of (1→3)-β-D-Glucan assay in presumptive *Pneumocystis jirovecii* pneumonia in immunocompromised patients. *Clin. Vacc. Immunol.* 16: 1524-1526.
61. Kocmanová, I., Ráčil, Z., Koukalová, D., Mayer, J., (2008). (1→3)-β-D-glucan measurement and its usefulness in the diagnosis of invasive fungal infections. *Klin. Mikrobiol. Infekc. Lek.* 14:88-92.
62. Obayashi, T., Negishi, K., Suzuki, T. and Funata, N., (2008). Reappraisal of the serum (1→3)-β-D-glucan assay for the diagnosis of invasive fungal infections—a study based on autopsy cases from 6 years. *Clin. Infect. Dis.* 46: 1864-1870.
63. Piscuilli, M.L. and Sax, P.E., (2008). Use of a Serum β-D-Glucan Assay for Diagnosis of HIV-Related *Pneumocystis jirovecii* Pneumonia in Patients with Negative Microscopic Examination Results. *Clin. Infect. Dis.* 46: 1928-1930.
64. Wiederhold, N.P., Najvar, L.K., Vallor, A.C., Kirkpatrick, W.R., Bocanegra, R., Molian, D., Olivo, M., Graybill, J.R. and Patterson, T.F., (2008). Assessment of (1→3)-β-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis. *Antimicrob. Agents Chemother.* 52; 1176-1178.
65. Persat, F., Ranque, S., Derouin, F., Michel-Nguyen, A., Picot, S. and Sulahian, A., (2008). Contribution of the (1→3)-β-D-Glucan Assay for the Diagnosis of Invasive Fungal Infections. *J. Clin. Micro.* 36: 1009-1013.
66. Marty, F. M. and Koo, S., (2008). Role of (1→3)-β-D-Glucan in the diagnosis of invasive aspergillosis. *Medical Mycology* 47: Suppl. 1: S233-240.
67. Ellis, M., Ramadi, B., Finkelman, M., Hedstrom, U., Kristenson, J., Ali-Zadeh, H., and Klingspor, L., (2007). Assessment of the clinical utility of serial β-D-glucan concentrations in patients with persistent neutropenic fever. *J. Med. Microbiol.* 57: 287-95
68. Girouard, G., Lachance, C., Pelletier, R., (2007). Observations on (1→3)-β-D-glucan detection as a diagnostic tool in endemic mycosis caused by *Histoplasma* or *Blastomyces*. *J. Med. Microbiol.* 56:1001-2.
69. Marty, F. M., Koo, S., Bryar, J., and Baden, L.R., (2007). (1→3)-β-D-glucan assay positivity in patients with *Pneumocystis (carinii) jirovecii* pneumonia. *Ann. Int. Med.* 147: 70-72.
70. Smith, P.B., Benjamin, D.K., Alexander, B.D., Johnson, M.D., Finkelman, M.A. and Steinbach, W.J., (2007). (1→3)-β-D-Glucan levels in pediatric patients: Preliminary data for the use of the beta-glucan test in children. *Clin. Vaccine Immunol.* 14: 924-925.
71. Egan, L., Connolly, P., Wheat, L. J., Fuller, D., Davis, T. E., Knox, K. S. and Hage, C. A. (2007). Histoplasmosis as a cause for a positive Fungitell® (1→3)-β-D-glucan test, *Medical Mycology*, 46:1,93–95
72. Odabasi, Z., Paetznick, V.L., Rodriguez, J.R., Chen, E., McGinnis, M.R. and Ostrosky-Zeichner, L., (2006). Differences in beta-glucan levels in culture supernatants of a variety of fungi. *Med. Mycol.* 44:267-72.
73. Pazos, C., Moragues, M.D., Quindos, G. and del Palacio, A., (2006). Diagnostic potential of (1→3)-β-D-glucan and anti-*Candida albicans* germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients. *Rev. Iberoam Micol.* 23: 209-215.
74. Mennink-Kersten, M.A., Ruegebrink, D., Wasei, N., Melchers, W.J. and Verweij, P.E., (2006). In vitro release by *Aspergillus fumigatus* of galactofuranose antigens, (1→3)-β-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. *J. Clin. Microbiol.* 44:1711-8.
75. Ostrosky-Zeichner, L., Alexander, B.D., Kett, D.H., Vazquez, J., Pappas, P.G., Saeki, F., Ketchum, P.A., Wingard, J., Schiff, R., Tamura, H., Finkelman, M.A. and Rex, J.H., (2005). Multicenter clinical evaluation of the (1→3)-β-D-glucan assay as an aid to diagnosis of fungal infections in humans. *Clin. Inf. Dis.* 41: 299-305.
76. Pazos, C., Ponton, J. and Del Palacio, A., (2005). Contribution of (1→3)-β-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: A comparison with serial screening for circulating galactomannan. *Journal of Clinical Microbiology* 43: 299-305.
77. Pickering, J.W., Sant, H.W., Bowles, C.A., Roberts, W.L. and Woods, G.L., (2005). Evaluation of a (1→3)-β-D-glucan assay for diagnosis of invasive fungal infections. *J. Clin. Microbiol.* 43:5957-62.
- Odabasi, Z., Mattiuzzi, G., Estey, E., Kantarjian, H., Saeki, F., Ridge, R., Ketchum, P., Finkelman, M., Rex, J. and Ostrosky-Zeichner, L., (2004). Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. *Clin. Inf. Dis.* 39:199-205.
78. Digby, J., Kalbfleisch, J., Glenn, A., Larsen, A., Browder, W. and Williams, D. (2003). Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. *Clin. Diagn. Laboratory Immunol.* 10: 802-805.

B. (1→3)-β-D-Glucan Kinetics

1. Jaijakul, S., et al., (2012). (1→3)-β-D-Glucan as a prognostic marker of treatment response in invasive candidiasis. *Clin. Inf. Dis.* 55: 521-526.
2. Koo, S., et al., (2012). Post-diagnosis kinetics of the (1→3)-β-D-glucan assay in invasive aspergillosis, invasive candidiasis, and *Pneumocystis jirovecii* pneumonia. *Clin. Microbiol. Infect.* 18:E122-127.
3. Sims, C.R., et al., (2012). Correlation of clinical outcomes with β-glucan levels in patients with invasive candidiasis. *J. Clin. Microbiol.* 50:2104-2106.
4. Held, J. and Wagner, D., (2011). β-D-Glucan kinetics for the assessment of treatment response in *Pneumocystis jirovecii* pneumonia. *Clin. Microbiol. Infect.* 17: 1118-1122.
5. Mikulska, M., Furfaro, E., Del Bono, V., Gualandi, F., Van Lint, M.T., Miletich, F., Bacigalupo, A. and Viscoli, C., (2011). Persistence of positive (1,3)-beta-glucan test after clearance of candidemia in HSCT recipients. *Clin. Vacc. Immunol.* 18: 518-519.



THE FUNGITELL® ASSAY REFERENCE LIST

Selected references for clinical, pre-clinical and basic research involving diagnostic (1→3)-β-D-glucanemia

C. (1→3)-β-D-Glucan & Galactomannan Diagnostic Performance

1. Ates, O., Metan, G., Dundar, T., Kiziltepe, M., Kocyigit, I., Unal, A., Sipahioğlu, M., Oymak, O., Tokgoz, B., (2013). Diagnosis of *Aspergillus niger* peritonitis in a peritoneal dialysis patient by peritoneal galactomannan and β-D-glucan detection. *Perit. Dial. Int.* 33:216-8.
2. Mosquera, R.A., Estrada, L., Clements, R.M., Jon, C.K., (2013). Early diagnosis and treatment of invasive pulmonary aspergillosis in a patient with cystic fibrosis. *BMJ Case Rep.* 18;2013. pii: bcr2013201360. doi: 10.1136/bcr-2013-201360.
3. Fontana, C., et. al., (2012). (1→3)-β-D-glucan vs. galactomannan antigen in diagnosing invasive fungal infections. *Open Microbiology Journal* 6: 70-73.
4. Acosta, J., Catalan, M., Del Palacio-Peréz-Medel, A., Lora, D., Montejó, J.C., Cuetara, M.S., Moragues, M.D., Ponton, J., Del Palacio, A., (2011). A prospective comparison of galactomannan in bronchoalveolar lavage fluid for the diagnosis of pulmonary invasive aspergillosis in medical patients under intensive care: Comparison with the diagnostic performance of galactomannan and of (1→3)-β-D-glucan chromogenic assay in serum samples. *Clin. Microbiol. Infect.* 17:1053-60.
5. Acosta J., Catalan M., Del Palacio-Pérez-Medel A., Montejó J.C., De-La-Cruz-Bértolo J., Moragues MD, Pontón J., Finkelman M.A., Del Palacio A., (2011). Prospective study in critically ill non-neutropenic patients: diagnostic potential of (1→3)-β-D-glucan assay and circulating galactomannan for the diagnosis of invasive fungal disease. *Eur. J. Clin. Microbiol. Infect. Dis.* 31:721-31.
6. Thornton, C.R., (2008). Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis. *Clin. Vaccine Immunol.* 15:1095-105.
7. Hachem, R.Y., Kontoyiannis, D.P., Chemaly, R.F., Jiang, Y., Reitzel, R. and Raad, I., (2008). Utility of galactomannan enzyme immunoassay and (1→3)-β-D-glucan in diagnosis of invasive fungal infections: low sensitivity for *Aspergillus fumigatus* infection in hematologic malignancy patients. *J. Clin. Micro.* 47: 129-133.
8. Ahmad, S., Khan, Z.U. and Theyyathel, A.M., (2007). Diagnostic value of DNA, (1→3)-β-D-glucan, and galactomannan detection in serum and bronchoalveolar lavage of mice experimentally infected with *Aspergillus terreus*. *Diagn. Microbiol. Infect. Dis.* 59:165-71.
9. Rafailidis, P.I., Falagas, M.E., Khan, Z.U., Ahmad, S., Mokaddas, E., Said, T., Nair, M.P., Halim, M.A., Nampoory, M.R. and McGinnis, M.R., (2007). Cerebral aspergillosis diagnosed by detection of *Aspergillus flavus*-specific DNA, galactomannan and (1→3)-β-D-glucan in clinical specimens. *J. Med. Microbiol.* 56:129-32.

D. (1→3)-β-D-Glucan Meta-Analyses

1. Karageorgopoulos, D.E., et. al., (2013). Accuracy of β-D-glucan for the diagnosis of *Pneumocystis jirovecii* pneumonia; a meta-analysis. *Clin. Microbiol. Infect.* 19:39-49.
2. Lamoth, F., et. al., (2012). β-Glucan Antigenemia Assay for the Diagnosis of Invasive Fungal Infections in Patients With Hematological Malignancies: A Systematic Review and Meta-Analysis of Cohort Studies From the Third European Conference on Infections in Leukemia (ECIL-3). *Clin. Infect. Dis.* 54:633-43.
3. Karageorgopoulos, D.E., Vouloumanou, E.V., Ntziora, F., Michalopoulos, A., (2011). β-D-Glucan assay for the diagnosis of invasive fungal infections: A meta-analysis. *Clin. Inf. Dis.* 52: 750-770.

E. (1→3)-β-D-Glucan Reagent-Related

1. Bassetti, M. and Bouza, E. (2017). Invasive mould infections in the ICU setting: complexities and solutions. *J. Antimicrob Chemother.* 72(suppl_1): Review.
2. Alonso, R., et. al., Alzheimer's disease and disseminated mycoses. (2014). *Eur. J. Microbiol. Infect. Dis.* 32: 795-801.
3. Issa, N.C., Koo S., Lynch R.C., Gay, C., Hammond, S.P., Baden, L.R., Ghobrial, I.M., Finkelman, M.A., Marty, F.M., (2011). Serum Galactomannan and (1→3)-β-D-Glucan Assays in Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia. *J. Clin. Microbiol.* 50: 1054-1056.
4. Marty, F.M., Lowry, C.M., Lempitski, S.J., Kubiak, D.W., Finkelman, M.A., and Baden, L. R., (2006) Reactivity of (1→3)-β-D-Glucan assay with commonly used intravenous antimicrobials. *Antimicrob. Agents Chemo.* 50: 3450-3453.
5. Finkelman, M.A. and Tamura, H., (2005). Detection and measurement of (1→3)-β-D-glucan. In "Toxicology of (1→3)-β-Glucans," Young, S.H. and Castranova, V, eds. CRC Press, New York.

F. Clinical Guideline-Related

1. Rhodes, A., Evans, L.E., Alhazzani, W. et. al. (2017). Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. *Intensive Care Med.* 43:304-377.
2. Lortholary, O. et. al. (2012) ESCMID* guideline for the diagnosis and management of *Candida* diseases 2012: diagnostic procedures. *Clin. Microbiol. Infect.* 18 (Suppl. 7): 9-18.
3. Rhunke, M. et. al. (2012). Diagnosis of invasive fungal infections in hematology and oncology guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). *Ann Oncol.* 23:823-33.
4. Marchetti, O., Lamoth, F., Mikulska, M., Viscoli, C., Verweij, P., Bretagne, S., (2011). ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. *Bone Marrow Transplant.* 47: 846-54.
5. Kullberg, B.J. et. al. (2011). European Expert opinion on the management of invasive candidiasis in adults. *Clin. Microbiol. Infect. Suppl.* 5: 1-12.
6. Maschmeyer, G., et. al. (2015). Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): Updated guidelines of the infectious diseases working party of the German Society of Haematology and Oncology (DGHO). *Ann Oncol.* 2015;26:21-33
7. Segal, B.H. et. al. (2008) Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. *Clin. Inf. Dis.* 47:674-683.
8. De Pauw, B. et. al., (2008) Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. *Clin. Infect. Dis.* 15;46:1813-21.



THE FUNGITELL® ASSAY REFERENCE LIST

Selected references for clinical, pre-clinical and basic research involving diagnostic (1→3)-β-D-glucanemia

G. Clinical Mycology Reviews

1. Fisher, B.T., (2013). The Role of Biomarkers for Diagnosis of and Therapeutic Decisions Related to Invasive Aspergillosis in Children. *Curr. Fungal Infect Rep.* 7:7-14.
2. Finkelman, M.A., (2010). *Pneumocystis jirovecii* infection: Cell wall (1→3)-β-D-glucan: Biology and diagnostic utility. *Crit. Rev. Microbiol.* 36: 271-81.
3. Ponton, J., (2009). Usefulness of biological markers in the diagnosis of invasive candidiasis. *Rev. Iberoam. Micol.* 26:8-14.

H. Miscellaneous

1. Fernandez-Silva, F., et. al., (2013). Evaluation of the Efficacies of Amphotericin B, Posaconazole, Voriconazole and Anidulafungin in a Murine Disseminated Infection by the Emerging Opportunistic Fungus *Sarocladium (Acremonium) kiliense*. *Antimicrob. Agents Chemother.* 57: 6265-9.
2. Vargas, S.A., et. al., (2013). Near-universal prevalence of *Pneumocystis* and associated increase in mucus in the lungs of infants with sudden unexpected death. *Clin. Inf. Dis.* 56: 171-179.
3. Mitchell, K.F. et. al., (2013). Role of Matrix β-1,3 Glucan in Antifungal Resistance of Non-*albicans Candida* Biofilms. *Antimicrob. Agents Chemother.* 57: 1918-1920.
4. Sav. H., et. al., (2012). The importance of bronchoalveolar lavage (BAL) sample for galactomannan, (1→3)-β-D-glucan and PCR tests. *Mikrobiol. Bul.* 46: 695-701.
5. Tasaka, S. and Tokuda, H., (2012). *Pneumocystis jirovecii* pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. *J. Infect. Chemother.* 18(6):793-806.
6. Shupp, J.W., Petraitiene, R., Jaskille, A.D., Pavlovich, A.R., Matt, S.E., Nguyen, D.T., Kath, M.A., Jeng, J.C., Jordan, M.H., Finkelman, M., Walsh, T.J., Shoham, S., (2011). Early serum (1→3)-β-D-glucan levels in patients with burn injury. *Mycoses* 55:224-7.
7. Hale, T.W., Bateman, T.L., Finkelman, M.A. and Berens, P.D., (2009). The absence of *Candida albicans* in milk samples of women with symptoms of ductal candidiasis. *Breastfeeding Med.* 4: 57-61.
8. Kondori, N., Edebo, L., and Mattsby-Baltzer, I., (2004). Circulating (1→3)-β-D-glucan and Immunoglobulin G subclass antibodies to *Candida albicans* cell wall antigens in patients with systemic candidiasis. *Clinical and diagnostic Laboratory Immunology.* 11(2):344-350.
9. Petraitiene, R., Petraitis, V., Hope, W.W., Mickiene, D., Kelaher, A.M., Murray, H.A., Mya-San, C., Hughes, J.E., Cotton, M.P., Bacher, J. and Walsh, T.J., (2008). CSF and Plasma (1→3)-β-D-glucan as surrogate markers for detection and therapeutic response of experimental hematogenous *Candida* meningoencephalitis. *Antimicrobial Agents and Chemotherapy.* 52: 4121-4129.



Reference List Publish Date:
September 2017

Corporate Headquarters
Associates of Cape Cod, Inc.
124 Bernard E. Saint Jean Drive
East Falmouth, MA 02536 USA
Tel: (508) 540-3444
www.acciusa.com

United Kingdom
Associates of Cape Cod Int'l., Inc.
Deacon Park, Moorgate Road
Knowsley, Liverpool L33 7RX
United Kingdom
Tel: (44) 151-547-7444
www.acciuk.co.uk

Europe
Associates of Cape Cod Europe, Inc.
Opelstrasse 14
D-64546 Mörfelden-Walldorf
Germany
Tel: (49) 61 05-96 10 0
www.acciusa.de